Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
Cardio Diagnostics Holdings (CDIO): Monitoring the Potential Move to $2.50

Cardio Diagnostics Holdings (CDIO): Monitoring the Potential Move to $2.50

Key Takeaways

  • The $2.50 objective used here is a technical and psychological milestone drawn from public market discussion, not an analyst consensus, because Cardio Diagnostics Holdings, Inc. (CDIO) lacks a meaningful set of current analyst price targets.
  • At a latest verified price near $1.89, reaching $2.50 would require a gain of roughly 32%, a substantial move for a micro-cap stock.
  • The 52-week range is exceptionally wide at roughly $0.97 to $7.91, reflecting the extreme volatility typical of early-stage, thinly traded biotechnology names.
  • The strongest potential supports are a new in-house CLIA-certified laboratory, expanding payer coverage, and its precision cardiovascular testing franchise.
  • The biggest risks are minimal revenue, recurring net losses, ongoing share dilution, and very thin institutional coverage.
  • Readers can find more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
  • Explore Trending AI Robots to see AI-driven strategies monitoring stocks and ETFs across changing market conditions.

How the $2.50 Price Objective Was Established

Cardio Diagnostics Holdings, Inc. (CDIO) is a Chicago-based, AI-driven precision cardiovascular diagnostics company that develops epigenetic and genetic blood tests, including Epi+Gen CHD and PrecisionCHD. As a micro-cap with a market capitalization of only about $5.6 million and negligible revenue, the company has essentially no current, credible analyst price-target coverage. Available third-party data is sparse and largely stale: some trackers reference a single dated target around $60 from early 2025, and others show an outdated low-to-high range near $4 to $8, but these figures predate the company's subsequent decline and heavy share dilution and do not form a usable consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Because no reliable analyst average exists, the $2.50 figure is a fallback objective grounded in identifiable technical and psychological milestones rather than a sell-side forecast. It sits meaningfully above the current price, above the 200-day moving average near $2.06, and well below the 52-week high near $7.91. It should be read as a discussion-level reference point, not a published analyst consensus.

Current Market Position and Path Toward the Target

The stock last traded near $1.89, with a 52-week range of roughly $0.97 to $7.91. Reaching $2.50 implies an upside of about 32%, a substantial move given the company's scale and liquidity. The path would most plausibly involve a sustained recovery above the 200-day moving average (around $2.06) and the psychologically important $2.00 level, followed by momentum toward $2.50 as the next round-number resistance zone.

Fundamentally, the business remains at a very early commercialization stage. Trailing twelve-month revenue is only about $15,000, while the company reported a third-quarter net loss of roughly $1.73 million, or $0.59 per share. Any meaningful share-price advance would likely depend on evidence of accelerating test volumes and reimbursement rather than on current earnings, which are negative. From what I see, this remains the core dynamic to watch.

What Could Support a Move Toward the Target

  • In-house laboratory capacity: the company launched its own high-complexity CLIA-certified laboratory in Iowa City, giving it end-to-end control over test processing.
  • Expanding payer coverage: Atlas Healthcare Physicians agreed to cover Epi+Gen CHD and PrecisionCHD, a step toward broader reimbursement.
  • Differentiated product franchise: its epigenetic-genetic tests target a large cardiovascular disease market, addressing gaps in traditional angiography.
  • Clean balance sheet: low debt and a strong current ratio provide some runway, though cash is finite.

What Could Prevent the Target From Being Reached

  • Minimal revenue: at roughly $15,000 in trailing twelve-month sales, commercialization remains in its infancy.
  • Persistent losses: negative EPS and negative free cash flow require continued external funding.
  • Dilution: shares outstanding rose approximately 63% year over year, which can pressure the stock price.
  • Thin coverage and liquidity: limited institutional ownership and sparse analyst coverage can amplify volatility in both directions.
  • Micro-cap risk: with a beta near 2.3, the stock is far more volatile than the broader market.

Technical Levels and Market Structure

The 50-day moving average sits near $1.84 and the 200-day moving average near $2.06, meaning the stock is trading between these two trend benchmarks. The $2.00 area is a key psychological level, and $2.50 represents the next notable round-number resistance zone. Above that, the prior 52-week high near $7.91 shows how quickly this low-float name has repriced in the past, while the 52-week low near $0.97 highlights the downside risk. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge momentum.

Time Horizon and What Investors Should Monitor

Analyst price targets, when available, typically reflect a roughly 12-month research horizon, but no current, dated institutional targets apply here, so no specific horizon should be assumed for the $2.50 objective. Investors should monitor upcoming earnings reports and revenue progression, reimbursement and coverage announcements, laboratory utilization data, any financing or dilution events, and the stock's ability to hold above its moving averages. Changes in the broader biotechnology and small-cap funding environment also matter.

Exploring AI Daily Buy/Sell Signals

In my own research process, Tickeron’s AI Daily Buy/Sell Signals have become a useful complement for volatile names like this one. The tool applies artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a thinly covered micro-cap like CDIO, it helps surface opportunities and track trend shifts more efficiently than manual methods alone. I find it particularly helpful for maintaining perspective amid the swings typical in this sector.

Final Assessment

Whether CDIO can reach $2.50 depends less on valuation and more on execution. The roughly 32% move required is substantial for a company generating almost no revenue, yet it is well within the range this stock has traveled over the past year. Supporting factors, including the new in-house laboratory and early payer coverage, provide a plausible catalyst narrative, while persistent losses, dilution, and minimal liquidity represent the principal obstacles. With no reliable current analyst consensus, the $2.50 level is best viewed as a technical reference point to monitor, not a forecast or guarantee of future performance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CDIO

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


CDIO in downward trend: 10-day moving average crossed below 50-day moving average on October 12, 2026

The 10-day moving average for CDIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

CDIO broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CDIO's RSI Indicator exited the oversold zone, 40 of 50 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CDIO as a result. In 41 of 64 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.

The Moving Average Convergence Divergence (MACD) for CDIO just turned positive on November 06, 2026. Looking at past instances where CDIO's MACD turned positive, the stock continued to rise in 21 of 38 cases over the following month. The odds of a continued upward trend are 55%.

CDIO moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +6.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDIO advanced for three days, in 113 of 154 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

The Aroon Indicator entered an Uptrend today. In 53 of 136 cases where CDIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 39%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 46 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. CDIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.654) is normal, around the industry mean (3.498). P/E Ratio (-0.566) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (322.581) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
311 West Superior Street
Phone
+1 855 226-9991
Employees
17
Web
https://www.cdio.ai
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.